← Back to Home

Alzheimer’s Blood Testing Moves Toward Japan: C2N and LSI Medience Partner to Seek Approval

PrecivityAD2 will seek to enter healthcare facilities through Japan’s clinical testing system. The test can help identify amyloid pathology in the brain, but regulatory review and insurance reimbursement remain hurdles between the agreement and actual patient use.

By SURL BioNews

When memory and cognition begin to change, patients need to understand not only the extent of their decline but also whether Alzheimer’s disease pathology is involved. C2N Diagnostics and Japan’s LSI Medience announced a partnership on November 10 to seek Japanese regulatory approval and commercialization of the PrecivityAD2 blood test, aiming to make this type of pathological assessment more accessible in routine clinical care.

The partnership has been formalized as a domestic sales agreement in Japan. According to LSI Medience’s announcement, the company will serve as the Japanese distributor and use its clinical testing services to advance access to the test through healthcare facilities. The companies’ English-language press release also states that LSI Medience will pursue insurance reimbursement. These are planned next steps and do not mean that the test has already been approved or covered by insurance in Japan.

PrecivityAD2 uses high-resolution mass spectrometry to analyze two blood markers: the amyloid-beta Aβ42/40 ratio and %p-tau217, which is related to tau protein phosphorylation. These are then combined into a score reflecting the likelihood of Alzheimer’s-related amyloid pathology in the brain. The test provides clues to pathology that must still be interpreted alongside the patient’s symptoms, medical history, and other clinical assessments.

According to materials released by the companies, the validation study supporting its U.S. approval included 1,142 people and used amyloid positron emission tomography or cerebrospinal fluid biomarkers as references. Results classified as “Positive” had a positive predictive value of 97.6%; those classified as “Negative” had a negative predictive value of 93.1%. In other words, these figures describe the proportion of results in each test category that agreed with the reference assessment in the study. They cannot be treated as a single accuracy rate applicable to everyone tested.

The study also retained a category with greater uncertainty: 17.3% of participants were classified as “Likely Positive,” and the positive predictive value for this category was 77.3%. Citing only the clearly positive and negative figures would leave out this group requiring further clarification. Predictive values are also affected by the prevalence of pathology in the population being tested, so the study results cannot be directly applied to screening Japan’s general population.

The boundaries of its intended use are equally clear. According to the announcement, the U.S. FDA approval recently obtained for PrecivityAD2 applies to adults aged 40 and older who already have signs or symptoms of cognitive impairment and are undergoing evaluation, and the test must be used alongside clinical judgment. It is not a standalone diagnostic tool and is not intended for general screening of asymptomatic populations. The scope of use and conditions ultimately approved in Japan will be determined by local regulatory review.

The agreement also extends existing research services into clinical applications. Mediford, part of PHC Group, will continue to provide researchers and pharmaceutical companies with services such as specimen transport and results reporting, while LSI Medience takes on efforts directed toward healthcare facilities. Regulatory review outcomes, reimbursement arrangements, and how the test is integrated into the clinical care pathway for cognitive impairment will determine how much practical difference this partnership can make for patients.

References

  1. C2N Diagnostics
  2. LSI Medience
  3. BioSpace (Business Wire press release)